热门资讯> 正文
Zentalis Pharmaceuticals任命Julie Eastland为首席执行官
2024-11-13 21:46
- Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced that Julie Eastland has been appointed Chief Executive Officer, President and Director, succeeding Kimberly Blackwell, who will remain as a strategic advisor to the Board of Directors.
- Eastland served as Chief Executive Officer at Harpoon Therapeutics until the company’s acquisition by Merck in early 2024.
- In addition to Eastland’s appointment, Ingmar Bruns, has been appointed Chief Medical Officer.
- The company also announced that Scott Myers has been appointed as Chairperson of the Zentalis Board of Directors.
- Source: Press Release
More on Zentalis Pharmaceuticals
- Zentalis stock rises after FDA lifts partial clinical hold on azenosertib studies
- Seeking Alpha’s Quant Rating on Zentalis Pharmaceuticals
- Historical earnings data for Zentalis Pharmaceuticals
- Financial information for Zentalis Pharmaceuticals
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
